The present teachings relate to a multiple component material and an apparatus to separate and concentrate the various components. More particularly, the present teachings relate to a container operable with a centrifuge to separate and concentrate various biological components.
Multi-phase or multi-component materials where solid and fluids are combined (slurries and suspensions, for example) may be separated into the respective solid, semi-solid, or fluid components and subcomponents thereof. Complex multi-component materials may be difficult to separate because of particle sizes, fluid viscosities, interactions between the materials, etc. Depending on the desired end use of a subcomponent, separation of some multi-component materials may be too labor intensive or time consuming to warrant separating the materials.
For example, in arthroplasty procedures, the materials removed from the subject during bone bed preparation or bone reaming include a mixture of cartilage, bone chips, surrounding blood and fluids, and the dense spongy material known as bone marrow. The bone reaming materials can include beneficial undifferentiated cells, such as mesenchymal stem cells, white blood cells, and platelets which may be used to expedite the healing of the injury site and incision or may be used as therapy in other procedures. To separate the bone reaming materials into the beneficial mesenchymal stem cells is a multi-step process and can occupy hours of preparation and waiting time. An exemplary separation process includes precipitating the unwanted cells via culturing, plating, incubating the preparation, and then washing and centrifuging the preparation several times to concentrate the desired stem cells. This process is time consuming, labor intensive, and inefficient—characteristics that are neither desirable in a self-paced laboratory environment, nor desirable under surgical conditions and time restraints. Accordingly, despite the vast applications of the undifferentiated cells, white blood cells, and platelets in bone reaming material, the extensive labor in separation is too burdensome and therefore, the bone reaming material or bone reaming “debris” is discarded.
Whole blood and fluids from the arthoplasty procedure may also be discarded despite the beneficial components. Like the bone reaming material, these fluids have fractions that may be used to expedite healing and promote tissue health. For example, the whole blood may be separated into platelets, red blood cells, and plasma by density in a device such as a centrifuge. Nonetheless, these methods do not provide a simple or efficient method to extract any more than one fraction and especially a fraction other than the top fraction. Even in these systems, multiple spins may be required to effectively separate the constituents without commingling the sample. These same difficulties may be encountered even using systems incorporating a float or other device that is disposed within the sample at the interfaces of the different fractions during the centrifuge process. Additionally, the current separation systems are generally designed to separate only same phase components and do not work with multiple states of matter such as partial fluid mixtures which contain macroparticles or large sized particles, such as the bone reaming materials described above.
Therefore, it is desired to provide a device to allow for collection of selected constituents from a multi-component material having macroparticles. It is desired to provide a device to allow for the easy and reproducible removal of a particular fraction which does not happen to be the top fraction of a sample. It is desired to remove the required sample without mixing the different fractions during the extraction process. In addition, it is desired to provide a device which allows for a consistent extraction of known volumes or concentrations of the fraction elements. Moreover, it is desired to separate and concentrate a multi-state composition with one centrifugation step.
An apparatus that separates and concentrates a selected fraction or component of a fluid, such as a biological fluid. For example, undifferentiated cells, such as mesenchymal stem cells, platelet fraction, buffy coat, or white blood cell fraction can be separated from bone reaming material, whole blood, bone marrow aspirate, and other materials. The apparatus, when used with a centrifuge, is generally able to create at least two fractions. It also provides for a new method of extracting the desired fraction or component or middle fraction from a sample.
The apparatus includes a container to be placed in a centrifuge after being filled with a sample. The apparatus can include a filtration system, a separation system, and an extraction system. The filtration system prevents the migration of undesired solids into the buoy system. The separation system includes a buoy or fraction separator, having a selected density that may be less than one fraction but greater than a second fraction, and is disposed in the container. In addition, a second buoy may be placed in the container with the first. The extraction system is connected to the buoy system or to the collection chamber such that the fraction in the container can be collected and drawn outside of the chamber. During the centrifuge processing, the buoy is forced away from a bottom of the container as the denser fraction collects at the bottom of the container. The buoy is generally able to physically separate the denser fraction from another fraction of the sample. The fractions can be withdrawn using the extraction system or member.
In addition to providing a first buoy and/or a second buoy, a buoy system may be provided. Generally, the buoy system may separate the sample into at least three fractions. The fractions may be separated or extracted from the container without substantially comingling the various fractions. Generally, a first buoy and a second buoy operate together to separate the sample into the various fractions and a syringe or tube may then be interconnected with a portion of the buoy system to extract the selected fractions. For example, a first buoy may be generally density tuned to a white blood cell fraction of a whole blood sample, and a second buoy tuned to a density less than the density of the undifferentiated cell fraction from bone reaming material.
According to various embodiments a method of forming at least one fraction for application relative to an anatomy is taught. The method may include obtaining a volume of a heterogeneous whole material and separating the material into the desired fraction(s). At least one of the fractions may be applied to the scaffold.
Further areas of applicability of the present teachings will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating various embodiments of the teachings, are intended for purposes of illustration only and are not intended to limit the scope of the teachings.
The present teachings will become more fully understood from the detailed description and the accompanying drawings, wherein:
The following description of various embodiments is merely exemplary in nature and is in no way intended to limit the teachings, its application, or uses. Although the following description exemplary refers to bone reaming material, whole blood, and/or bone marrow aspirate separation, it will be understood that the present teachings may be used to separate and concentrate any appropriate material. It will be further understood that many multi-component materials containing macroparticles may be separated. The components or fractions are generally inter-mingled in the whole sample but may be separated with a centrifuge device that causes increased local gravity or gravitational forces.
With reference to
Although the tube 12 is described here as a cylinder, it will be understood that other shapes may be used, such as polygons. The internal portions, such as the cap 18, filtration system 13, and buoy 14, 300, would also include this alternate shape. Preferably the tube 12 is formed of a thermal plastic material which is flexible under the forces required to separate multi-component biological materials such as a mixture of bone reaming material and whole blood. The tube 12 may be made of a material that includes the properties of both lipid and alcohol resistance. These properties help increase the separation speed and decrease the amount of material which may cling to the tube wall 23. For example, Cyrolite MED2® produced by Cyro Industries of Rockaway, N.J. may be used to produce the tube 12.
The tube 12 has a tube wall 23 with a thickness of between about 0.01 millimeters and about 30.0 millimeters, although the tube wall 23 may be any appropriate thickness. The thickness of the tube wall 23 allows the tube wall 23 to flex during the centrifuge process yet be rigid enough for further processing of a bone reaming debris and blood sample disposed in the tube 12. The tube 12 is closed at the bottom end 12b with a tube bottom 24 formed of the same material as the tube wall 23 and is formed integrally therewith. Generally the tube bottom 24 has a thickness which is substantially rigid under the forces required to separate the sample such that it does not flex.
The cap 18 provides a structure to substantially close the tube 12. The cap 18 particularly includes a plate 26 that has an external circumference substantially equal to the external circumference of the tube 12. Extending from the plate 26 and into the tube 12 is a flange 28. The external circumference of the flange 28 is substantially equal to the internal circumference of the tube 12. In this way, the cap 18 substantially closes the tube 12. It will be understood the cap 18 may be in any form so long as the cap 18 substantially closes and/or seals the tube 12 when installed.
The filtration system 13 is generally near the open end 12a of the tube. The filtration system 13 prevents migration of unwanted solid materials, such as macroparticles 32, through the filter and past the buoy 14, 300. The macroparticles 32 can be used for other purposes, such as void filling, but can be selected to not be further separated within the tube 12.
The filtration system 13 can comprise a mesh 30. The mesh 30 can be made of a rigid material such as high molecular weight PTFE. The mesh 30 can be rigid enough to support a mass during a centrifuge procedure. Alternatively, or in addition thereto, a support can be provided to support the mesh and the macroparicles during a selected procedure. For example, a filter plate 31 can be provided to support the mesh 30. The filter plate 31 can includes spacers large enough to allow a material to pass there through, but also support the mesh 30.
The mesh 30 can have a pore or mesh size that is of a sufficient diameter to prevent passage of unselected solid materials or macroparticles 32 through the filtration system 13. An example mesh size useful in the separation and concentration of a mixture of bone reaming material and whole blood is from about 10 micrometers to about 200 micrometers. In various embodiments, the mesh size is less than about 50 micrometers. It is understood that the mesh size may be modified depending on the fine or coarse nature of the bone reaming and the resultant sized macroparticles 32. As used herein, “macroparticle” refers to a solid or semi-solid material having a greater diameter than the pores used in the filtration system 13. For example, where the mesh 30 has a pore size of about 50 micrometers, the macroparticle 32 has a greatest cross-section length of greater than about 50 micrometers. In yet another example, where the mesh size is about 1 centimeter, the macroparticle 32 would have a cross-section length of greater than about 1 centimeter.
The filtration system 13 may be provided to be separable from the tube 12. For example, a seam or break 34 can be formed on the tube 12 such that the filtration system 13 and macroparticles 32 collected therein can be easily removed from the tube 12. The break 34 may include perforations or scoring that allows for removal either by hand manipulation from a user (such as snapping off the filtration system) or require the use of a tool to cut or remove the filtration member. As depicted in
As illustrated in
The separation system 10 can also includes the buoy 14, 300 to assist in separation and extraction of selected fractions from the whole sample. The buoys 14, 300 can include an upper or collection face 46 that defines an inverse cone or concave surface. Generally the cone has an angle of between about 0.5° to about 45°, and may be about 0.5° to about 90° from a vertical axis, wherein the apex of the cone is within the buoy 14, 300. The collection face 46 forms a depression in the buoy 14, 300 which collects and concentrates material during the separation process. Additionally, the buoy 14, 300 has a bottom face 40 that defines an inverse cone, dome, or covered surface. The buoy bottom face 40 includes an apex 42 that engages the tube bottom 24 before a buoy edge 44 engages the tube bottom 24. The buoy 14, 300 includes a material that is a substantially rigid such that the buoy edges 44 never meet the tube bottom 24. Therefore, there is a gap or free space 46 formed between the buoy edge 44 and the tube bottom 24 along the perimeter of the buoy 14, 300.
The separator 10 is generally provided to separate a multi-component material that can have macroparticles 32 that includes various components or constituents of varying densities that are commingled or mixed together. The separator 10 includes the buoy 14, 300 that is of a selected density depending upon a selected constituent of the multi-constituent material. Although the buoy 14, 300 may be tuned or of any selected density, the following example relates to separation of a bone reaming debris and whole blood mixture into various components. Therefore, the buoy 14, 300 will be discussed to include a selected density relative to bone reaming material and whole blood separation. It will be understood, however, that the buoy 14, 300 may be of any appropriate density depending upon the multi-component fluid being separated.
The buoy 14, 300 may be formed of any appropriate material that may have a selected density. With bone reaming materials, selected materials can include white blood cells, platelets, or undifferentiated cells, including, but not limited to mesenchymal stem cells. For example, when the separator 10 is to separate blood, the buoy 14, 300 generally has a density which is greater than that of platelets, red blood cells, and white blood cells in a bone reaming material and whole blood sample, but less than the undifferentiated cell fraction of the sample. For bone reaming material and whole blood mixtures, the density of the buoy 14, 300 is generally between about 1.02 g/cc and about 1.09 g/cc. This range is sufficient to separate at least red blood cells from the other fractions. The bone reaming debris and whole blood mixture (or saline) provides a choice of several desirable fractions, such as the white blood cells, platelets, and undifferentiated cells discussed herein. The value of 1.02 g/cc to about 1.09 g/cc is given only as a benchmark, assuming that the desired collection fraction is the platelet fraction or the undifferentiated stem cells as the value segregates the white and red blood cells from the other fractions. If for example, a different fraction was desired for collection, the density fraction, or a slightly higher density, would be an appropriate for the buoy to separate the undesired fraction.
To achieve the selected density, the buoy 14, 300 may be formed as a composite or multi-piece construction, including a plurality of materials. Particularly, a first or outside portion 48 defines the collection face or surface 38 and the buoy edge 44 and is formed of the same material as the tube 12. The outside portion 48 defines a cup or void into which a plug or insert 50 is placed. The insert 50 has a mass such that the density of the entire buoy 14, 300 is within the selected range, for example the range described above. Generally, a high density polyethylene may be used, but the material and size of the insert 50 may be altered to produce the desired density of the buoy 14, 300. Alternatively, the buoy 14, 300 may be formed of a single suitable material that has a density in the selected range. Nevertheless, the buoy 14, 300 formed unitarily or of a single material would still include the other portions described in conjunction with the buoy 14, 300.
The outside portion 48 of the buoy 14, 300 also defines the outside circumference of the buoy 14, 300. The outside circumference of the buoy 14, 300 is very close to the internal circumference of the tube 12. Due to the operation of the buoy 14, 300, however, described further herein, there is a slight gap between the outside of the buoy 14, 300 and the inside of the tube 12. Generally, this gap is between about 1 and about 10 thousandths of an inch around the entire circumference of the buoy 14, 300. Generally, it is desired that the distance between the outside circumference of the buoy 14, 300 and the inside circumference of the tube 12 is great enough to allow a selected material or component to pass. For example, in bone reaming material the distance is selected so that white and red blood cells may pass through the gap without being lysed, damaged, or activated.
Referring to
The first buoy 102 of the buoy system 100 may be generally similar in geometry to the buoy 14, 300. It will be understood that the first buoy member 102 may be formed in the appropriate manner including shape or size to achieve selected results. Nevertheless, the first buoy member 102 generally includes an exterior diameter that may be slightly smaller than the interior diameter of the tube 12. Therefore, the first buoy member 102 may be able to move within the tube 12 during the centrifugal process. Also, as discussed above, the tube 12 may flex slightly during the centrifuging process, thus allowing the first buoy member 102 to include an exterior diameter substantially equivalent to the interior diameter of the tube 12. As discussed further herein, during the centrifugation process, a portion of the fraction of a sample may pass between the exterior wall of the first buoy member 102 and the tube 12.
The first buoy member 102 may generally include a density that is substantially equivalent to a first or selected fraction of the sample. If the sample to be separated includes bone reaming material and is desired to separate the white/red blood cells from the other portions of the sample, the first buoy member 102 may have a selected density that may be about 1.00 grams per cc (g/cc) to about 1.10 g/cc. It will be understood that the density of the first buoy member 102 may be any appropriate density, depending upon the fraction to be separated, and this range of densities is merely exemplary for separating white/red blood cells from a whole blood sample.
In addition, the first buoy member 102 includes a collection face or area 108 at a proximal or upper portion of the first buoy member 102. The collection face 108 generally defines a concave area of the first buoy member 102 and may have a selected angle of concavity. The buoy assembly 100 defines a central axis D. The collection face 108 defines a surface E that is formed at an angle γ to the central axis D of the buoy system 100. The angle γ may be any appropriate angle and may be about 0.5° to about 90°. The angle γ may, however, be between about 45° and 89.5°. Nevertheless, it will be understood that the angle γ may be any appropriate angle to assist in collection of a selected fraction or portion of the sample by the first buoy member 102.
A bottom or lower surface 110 of the first buoy member 102 may define a bottom face. The bottom face 110 may also be formed at an angle D relative to the central axis D. The bottom surface 110 defines a surface or plane F that may be formed at an angle Δ relative to the central axis D of the buoy system 100. The angle Δ may be any appropriate angle and may be about 90° to about 180°. For example, the angle Δ may be about 105°. Similarly to the buoy bottom face 40, the bottom surface 110 defines an apex 112 that may first engage the bottom 12b of the tube 12, such that most or the majority of the bottom surface 110 does not engage the tube 12. As illustrated further herein, the apex 112 allows for a free space or gap to be formed between the bottom face 110 of the first buoy member 102 and the bottom 12b of the tube 12.
The second buoy member 104 may include an outer diameter substantially equivalent to the outer diameter of the first buoy member 102. Therefore, the second buoy 104 may move with the first buoy 102, particularly if the second buoy 104 is interconnected with the first buoy 102 with the buoy central cylinder 106. Nevertheless, the second buoy member 104 may be allowed to move substantially freely within the tube 12 during the centrifuging process.
The second buoy member 104 also includes an upper or superior surface 114 that defines a plane G that is formed at an angle relative to the central axis D of the buoy system 100. The angle ε of the plane G relative to the central axis D of the buoy system 100 may be any appropriate angle. For example, the angle ε may be about 90° to about 180°. Generally, the angle ε may assist in allowing a selected fraction or a portion of the sample to pass over the top surface 114 and past the second buoy member 104 during the centrifuging process.
The second buoy member 104 also define a bottom or inferior surface 116 that also defines a plane H that may be formed at an angle K relative to the central axis D of the buoy system 100. The angle K may be any appropriate angle, such as about 90° to about 150°. Nevertheless, the angle K may be convex and substantially complimentary to the angle γ of the collection face 108 that may be concave of the first buoy member 102. For example, if the angle γ0 is about 80°, the angle K may be about 80° as well so that the surfaces 316 and 308 mate as the first buoy member 102 engages the second buoy member 104. This may be for any appropriate reason, such as extraction of a fraction that may be disposed near the collection face 108 of the first buoy member 102. Nevertheless, the angle K may be any appropriate angle as the angle γ.
The second buoy member 104 may be formed to include any appropriate density. For example, the second buoy member 104 may include a density that is less than the plasma fraction of a bone reaming material and whole blood sample. It will be understood that the second buoy member 104 may include any appropriate density and a density that is less than the undifferentiated cell and/or platelet fractions of a bone reaming material blood sample is merely exemplary. Nevertheless, if a bone reaming material sample is desired to be separated and the plasma sample is to be substantially separated from another fraction, the second buoy member 104 may include a density that is less than the plasma fraction. Therefore, the density of the second buoy member 104 may be about 0.01 g/cc to about 1.03 g/cc.
The buoy post 106 may operably interconnect the first buoy member 102 and the second buoy member 104. The buoy post 106 may be any appropriate connection member. The buoy post need not be a single cylindrical portion. For example the buoy post 106 may include one or more members interconnecting the first buoy member 102 and the second buoy member 104, such as around a perimeter thereof. In addition, the buoy post 106 may include any appropriate shape or geometry.
The buoy system post 106 may be rigidly affixed to the first buoy member 102 and the second buoy member 104, such that the first buoy member 102 may not move relative to the second buoy member 104 and vice versa. Alternatively, the buoy post 106 may be slidably connected to either or both the first buoy member 102 and the second buoy member 104. According to various embodiments, the buoy post 106 is generally fixedly connected to the first buoy member 102 and slidably interconnected to the second buoy member 104. The buoy post 106 may include a catch portion or lip 120 that is able to engage a portion of the second buoy member 104, such that a range of travel of the second buoy member 104, relative to the first buoy member 102 is limited. Nevertheless, the range of travel of the second buoy member 104 towards the first buoy member 102 may be substantially unlimited until the second buoy member 104 engages the first buoy member 102.
The buoy post 106 may also define a central cannula or bore 122. The post bore 122 may include a connection portion 124 substantially defined near an upper or a proximal end of the buoy post 106. This may allow for interconnection of various components with the buoy post 106, such that various components may be moved through the bore 122 from an exterior location. The buoy post 106 may also define a port or cannula 126 that connects the post cannula 122 with the collection face 108. Therefore, a substance may travel through the post cannula 122 and through the port 126. Various substances may then be provided to or removed from the collection face 108 of the first buoy member 102.
The tube 12 may include the cap 18 that further defines a plasma valve or port 20. Extending through the cap 18 and interconnecting with a first flexible tube or member 54, the plasma port 20 may be used to extract plasma of the sample that is positioned above the second buoy member 104. The tube 12 may also define a second port 21, which may also be referred to as a plasma rich port (PRP). As discussed herein, a second flexible member, such as a flexible tube 21a, may interconnect the PRP port 21 and a connection portion 124 of a buoy cylinder 106.
Other portions of the separator system 10, particularly those portions of the tube 12 and the cap 18 that have various valves connected therewith may be included in the tube 12 and used with the buoy system 100. Nevertheless, once the buoy system 100 is interconnected, it may be positioned in the interior of the tube 12 and the syringe 200 used to place a sample into the tube 12.
The multi-component sample may be positioned in the separator 10 adjacent to the filtration system 13 for separation and concentration. The bone reaming material, whole blood, bone marrow aspirate, or other materials may be positioned by inserting the materials using a syringe through the port 22 or by removing the cap 18 and spreading the multi-component material into the region above the filtration system 13. In the latter placement method, the cap 18 is screwed or otherwise secured into place on the separator 10. Additional materials can be added to the multi-component sample to maintain the integrity of the sample, such as an anticoagulant. It will also be understood that various centrifuge times or forces may be altered depending upon the exact material that is being separated with the separator 10. It will also be understood that the separation of bone reaming material, a mixture of whole blood and bone reaming material, or whole blood, are merely exemplary of the materials that may be separated using the separator 10. It will be understood that two buoys 102 and 104 may generally be near one another when the sample is positioned in the tube 12, but are illustrated apart for clarity of the present discussion.
After the sample is positioned within the tube 12, as described above, a cap may be positioned over the port 22, such that the sample is not allowed to escape from the tube 12. After the sample is placed in the tube 12 and the cap 52 placed on the port 22, the tube 12 including the sample and the buoy system 100 may be centrifuged. The system 10 may remain stationary for a selected amount of time prior to centrifuging to allow the components of the bone reaming material and whole blood mixture, other than macroparticles 32, such as bone fragments, cartilage, etc. to transverse the filter and collect in the tube 12.
With reference to
During the centrifuge process the white/red bloods cells of the white/red blood cell fraction 222 force the buoy 14, 300 in the direction of the top 12a of the tube 12 because the buoy 14, 300 is less dense than the white/red blood cell fraction 222. Although the bone reaming material, including the white/red blood cells is loaded above the buoy 14, 300, the red blood cells are able to move between the buoy 14, 300 and the tube wall 23 because the circumference of the buoy 14, 300 is less than the internal circumference of the tube 12. During the centrifuge process the buoy 14, 300 stops at an interface of a plasma fraction 224 and the white/red blood cell fraction 222 because of the selected or tuned density of the buoy 14, 300.
With particular reference to
A first fraction 130 may be positioned between the bottom face 110 and the bottom of the tube 24. A second fraction may be positioned between the collection face 108 and the bottom surface 116 of the second buoy 104. In addition, a third fraction may be positioned between the upper surface 114 and the cap 18 of the tube 12. Generally, the first fraction 130, the second fraction 132, and the third fraction 134 are substantially physically separated with the buoy system 100. During the centrifugation process, the tube 12 may flex slightly to allow for ease of movement of the buoy system 100 through the tube 12 and the sample. Nevertheless, the buoy system 100, during the centrifugation process, substantially creates the three fractions 130, 132, and 134 without the operation of an operator. Therefore, the formation of at least three fractions may be substantially simultaneous and automatic using the buoy system 100.
The buoy system 100 substantially separates the fractions 130, 132, and 134, such that they may be easily removed from the tube 12. For example, with reference to
It will be understood that the second tube 21a may also be used. The extraction syringe 140 may be interconnected with the PRP 21 that is interconnected with the connection portion 124 of the buoy cylinder 106. As discussed herein the buoy cylinder allows access to the platelet rich area between the buoy portions. Thus, it will be understood, that access may be obtained and the platelet rich portion of the sample, between the two buoys, may be extracted in a plurality of ways. The illustrations and method described herein is merely exemplary.
Alternatively, if the post 106 is not provided other portions may be provided to gain access to the second fraction 132. For example, if a plurality of members are provided around the perimeter of the first buoy 102 and the second buoy 104 a valve portion, such as a puncture-able valve, may be provided in the second buoy 104 to be punctured with an object. In this way an extraction needle may puncture the valve to gain access to the second fraction 132. Regardless, it will be understood that the buoy system 100 may be able to form a plurality of fractions, such as the three fractions 130, 132, and 134 and at least the second fraction 132 may be extracted without substantially commingling the various fractions.
During the extraction of the second fraction 132 through the cannula 122, the second buoy member 104 may move in the direction of arrow M towards the first buoy member 102. As described above, the collection face 108 of the first buoy member may include an angle γ that is substantially complementary to the bottom face 116 of the second buoy member 104. Therefore, if the second buoy member 104 is allowed to move along the buoy cylinder 106, the bottom face 116 of the second buoy member 104 may be able to substantially mate with the collection face 108 of the first buoy member 102. Alternatively, if the second buoy member 104 is not allowed to move, the second buoy member may be provided with a vent port or valve, such that the extraction of the second fraction 132 from the collection face 108 may not be hindered by the buildup of undesirable forces. Nevertheless, if the second buoy member 104 may move, the interaction of the bottom face 116 of the second buoy member 104 may assist in substantially removing the entire second fraction 132 from the tube 12. As described above, the bottom face 84 of the plunger 16 may also serve a similar purpose when engaging the collection face 46 of the buoy 14, 300.
Once the second fraction 132 has been extracted from the tube 12, the second buoy member 104 may substantially mate with a portion of the first buoy member 102. As discussed above, the second buoy member 104 may substantially only mate with the first buoy member 102 if the second buoy member 104 is able to substantially move relative to the first buoy member 102. Therefore, it will be understood that the second buoy member 104 need not necessarily mate with the first buoy member 102 and is merely exemplary of an operation of various embodiments. Nevertheless, once the second fraction 132 has been extracted from the tube 12, the port 21 may be used in conjunction with a selected instrument, such as a plasma extraction syringe 200 to remove the plasma or the third fraction 134 from the tube 12 using the extraction tube 54 interconnected with the port 20.
As described above, the tube 54 allows for extraction of the third fraction 134 from the tube 12 without commingling the third fraction 134 with the remaining first fraction 130 in the tube 12. Therefore, similar to the separator and extraction system 10, three fractions may be substantially formed within the tube 12 with the buoy system 100 and may be extracted without substantially commingling the various fractions. Once the third fraction 134 is extracted from the tube 12, the buoy system 100 may be removed from the tube 12, such that the first fraction 130 may be removed from the tube 12. Alternatively, the first fraction 130 may be discarded with the tube 12 and the buoy system 100 as a disposable system. Alternatively, the system may be substantially reusable, such that it can be sterilized and may be sterilized for various uses.
The description of the method of use of the buoy system 100 is exemplary of a method of using a system according to various other embodiments. It will be understood, however, that various specifics may be used from various embodiments to allow for the extraction of selected fractions. For example, the centrifugation process may be substantially a single step centrifugation process. The buoy system 100, according to various embodiments, may allow for the formation of three fractions during a single centrifugation process.
The separator 10 is then spun in the centrifuge in a range between about 1,000 and about 8,000 RPMs. This produces a force between about 65 and about 4500 times greater than the force of normal gravity, as generally calculated in the art, on the separator 10 and the bone reaming material sample placed in the separator 10. At this force, the more dense material in a bone reaming material sample is forced towards the bottom 12b of the tube 12. The dense material, such as white and red blood cells or a white/white/red blood cell fraction 222, collects on the tube bottom 24. Because the buoy 14, 300 has a density that is less than the white/red blood cell fraction 222, it is forced in a direction toward the top 12a of the tube 12 in the centrifuge. Nevertheless, because the buoy 14, 300 is denser than a plasma fraction 224, the buoy 14, 300 does not reach the top 12a of the tube 12.
Referring to
In embodiments utilizing the piston, the cap 18 also includes a depth gage port 62. Extending from the plunger 60 and through the depth gage port 62 is a first plunger port 22. A depth guide or gage 38 includes a female connector 25 adapted to connect with the first plunger port 22. The depth gage 38 also includes a depth gage housing or cannula 28. The depth gage housing 66 defines a depth gage bore 68. Incorporated in the housing 66 and extending distal from the end mating with the plunger is a neck 70. The neck 70 includes external neck threads 72. The external neck threads 72 are adapted to engage appropriate internal threads of a mating member.
The mating member may include a compression nut 74 that mates with the external neck threads 72 to lock a depth gage rod 76 in a predetermined position. A split bushing 39 is also provided to substantially seal the depth gage housing 66 when the depth gage rod 76 is locked in place. The depth gage rod 76 extends through the depth gage housing 66 and terminates at a rod handle 78. The rod handle 78 may be a form easily manipulated by a human operator. The rod 76 extends coaxially with axis A of the tube 12. The depth gage rod 76 extends through the plunger 60 a predetermined distance and may be locked at that distance with the compression nut 74.
The plunger 60 includes a plunger front or collection face 84 and a plunger wall 80 that extends from the plunger front face 84. The plunger wall 80 extends relatively perpendicular to the plunger front face 84 and substantially parallel to the tube wall 23. Extending from the center of the plunger 60 is a sample collection projection 82. Extending from the top of the collection projection 82 is the first plunger port 22. The sample collection projection 82 includes a plunger sample collection bore 68 defined therethrough. The plunger sample collection bore 68 terminates at a sample collection aperture 86 that is substantially in the center of the plunger front face 84. The plunger front face 84 also defines an inverse cone where the sample collection aperture 86 is the apex of the cone. The plunger front face 84 defines a cone with an angle substantially similar or complimentary to the collection face 46 of the buoy 14, 300. In this way, the plunger front face 84 may mate substantially completely with the collection face 46 for reasons described more fully herein.
The plunger 60 also includes a back face 88. Extending from the plunger front face 84 to the back face 88 is a bore 74. A check valve 90 is operably connected to the bore 74. The check valve 90 allows a liquid to move from the plunger front face 84 to the back face 88 while not allowing the liquid to move from the back face 88 to the plunger front face 84. Therefore, the check valve 90 is substantially a one-way valve which allows a material to move in only one direction. The check valve 90 may also operate automatically allowing flow in only one predetermined direction. Alternatively, the check valve 90 may be operated manually and include a portion extending from the check valve 90 requiring manipulation to stop or start a flow through the check valve 90.
The plunger 60 may be made out of any appropriate material which does not interfere with the separation of the fractions of the fluid, such as whole blood. The plunger 60, however, is made of a material that is flexible or at least partially deformable. A flexible material allows the plunger 60 to have an external circumference defined by the plunger walls 63 that is substantially equal to the internal circumference of the tube 12. Because of the deformability of the plunger 60, however, the plunger 60 is still able to move within the tube 12. The plunger 60 is able to move through the tube 12 and also substantially wipe the interior of the tube wall 23. This creates, generally, a moveable seal within the tube 12. Thus, substantially no material escapes the action of the separator 10 when the plunger 60 is plunged into the tube 12. This also helps concentrate the portion of the sample desired to be collected, described more fully herein.
Formed through the center of the plate 26 is the depth gage port 62. The depth gage port 62 is also adapted to receive the sample collection projection 82. The first plunger port 22 extends above the plate 26 through the depth gage port 62. The circumference of the depth gage port 62 is substantially equal to the external circumference of the sample collection projection 82 such that a liquid seal is formed. The plate 26 defines a sample face 84 that includes an interior side of the cap 18. The area between the sample face 84 of the cap 18 and the back face 88 of the plunger 60 define a plasma collection area 92. Although the plasma collection area 92 is exemplary called the plasma collection area, it will be understood that the plasma collection area 92 may also collect any appropriate fraction of the sample that is positioned within a separator 10. The plasma collection area 92 is merely an exemplary name and an example of what material may be collected in the area of the separator 10. As discussed herein, the separator 10 may used to separate whole blood into various fractions, therefore the plasma collection area 92 is used to collect plasma. The plasma collection area 92 also allows a space for the check valve 90 to be installed.
A second bore 94 is formed in the plate 26. Extending through the second bore 94 is the fraction collection valve 20. In liquid communication with the fraction collection valve 20 is a plasma collection tube 54. The plasma collection tube 54 has a length such that the plasma collection tube 54 is able to extend from the fraction collection valve 20 to substantially the tube bottom 24. The plasma collection tube 54, however, is flexible enough such that it may be folded or compressed to fit within the plasma collection area 92 when the plunger is substantially near the top 12a of the tube 12. The plasma collection tube 54 may also be connected to a hose barb 93 that includes a plasma collection bore 93a. The plasma collection bore 93a is substantially level with the plunger back face 88. Alternatively, the plasma collection bore 93a may be positioned below the plunger back face 88 but in fluid communication with the plasma collection tube 54.
The outboard side of the fraction collection valve 20 may include external threads 94 to mate with internal threads of a plasma valve cap 96. Therefore, the fraction collection valve 20 may be selectively opened and closed via the plasma valve cap 96. It will be understood, however, that other appropriate means may be used to open and close the fraction collection valve 20 such as a clip or a plug. It will be understood that the fraction collection valve 20, plasma collection tube 54, plasma bore 23a may be used to collect any appropriate material or fraction from the separator 10.
Also formed in the plate 26 is a vent bore 98. The vent bore 98 allows air to flow into the collection area 92 as the plunger 60 is being plunged into the tube 12. The vent bore 98 may include an air filter 101 such that liquid cannot escape from the tube 12. The air filter 101 allows air to enter or escape from the collection area 92 while maintaining the liquid seal of the tube 12 produced by the cap 18.
Selectively attachable to the first plunger port 22 is the depth gage 38. The female connector 24 interconnects the depth gage housing 66 to the first plunger port 22. Internal threads in the female connector 24 mate with an external thread 103 formed on the first plunger port 22. It will be understood, however, that other engagement mechanisms between the depth gage 38 and the plunger 60 may be used. For example, a snap connection rather than a threaded connection between the two may be used.
The depth gage housing 66 is formed to be substantially rigid. Suitable materials, when sized properly, include polycarbonate and CYRO MED2®. The material preferably is both rigid and does not substantially react with the sample. It is rigid enough to provide a mechanism to plunge the plunger 60 into the tube 12. In addition the external circumference of the depth gage housing 66 is substantially equal to the circumference of the depth gage port 62 in the plate 26. Therefore, as the plunger 60 is being plunged into the tube 12 with the depth gage 38, no liquid material is allowed to escape around the depth gage housing 66 and through depth gage port 62.
Formed within the depth gage housing 66 is the bore 68 which receives the depth gage rod 76. The depth gage rod 76 extends through the sample collection bore 68 of the sample collection projection 82 and protrudes through the sample collection aperture 86 a predetermined length. The depth gage rod 76 extends through the sample collection aperture 86 a length such that when an end 105 of the depth gage rod 76 meets the buoy 14, 300, the volume defined by the collection face 46 and the plunger front face 84 is between about 5 percent and about 30 percent of the total volume of the sample that the tube 12 holds. The projection of the depth gage rod 76 allows for an easily reproducible collection amount and concentration over several trials.
The compression nut 74 locks the depth gage rod 76 in the predetermined position. Nevertheless, once the plunger 60 has been plunged to the desired depth in the tube 12, the compression nut 74 may be loosened so that the depth gage rod 76 may be removed from the plunger 60 and the depth gage housing 66 without moving the plunger 60. A syringe or other appropriate device may then be affixed to the external neck threads 72 of the depth gage 38 to extract the fraction or phase that is between the plunger front face 84 and the collection face 46. As described further herein, the fraction or phase that is left between the plunger front face 84 and the collection face 46 may be the undifferentiated cells or platelets of a bone reaming material sample. Nevertheless, it will be understood that the fraction between the plunger front face 84 and the collection face 46 may be any appropriate fraction of the sample that is disposed in the separator 10.
With reference to
With reference to
A cap 220 is then placed over the first plunger port 22 to substantially seal the tube 12. Similarly, whole blood or saline may be added to the tube to increase the viscosity of the bone reaming material. The whole blood or saline may also be introduced using the plunger port 22.
On or near collection face 46 is a third fraction 226 including a small, yet concentrated, amount of red blood cells, white blood cells, and a substantial portion of the platelets and undifferentiated cells of the bone reaming material sample. Although the undifferentiated cells are also present near the collection face 46 at this point the solid portions of the buffy coat are more compressed against the collection face 46. The position of the buoy 14, 300 also helps in this matter. Because the buoy 14, 300 is a single body it defines the interface of the plasma fraction 224 and the white/red blood cell fraction 222. Also the density of the buoy 14, 300 assures that it has not passed into the plasma fraction 224. Therefore, the fractions remain separated after the centrifuge process. In addition because the buoy 14, 300 is tuned to the density of the white/red blood cell fraction 222, it is not affected by variations in the density of the plasma fraction 224 and the position of the buoy 14 can always be at the interface of the white/red blood cell fraction 222 and the plasma fraction 224.
With particular reference to
The plunger 60 is plunged into the tube 12 until the point where the end 105 of the depth gage rod 76 reaches the buoy 14, 300. The volume left in the collection face 46 is the third fraction 226 and is determined by the depth gage 38. It may be adjusted by selectively determining the amount that the depth gage rod 76 extends below the plunger front face 84. By adjusting the depth gage 38, the concentration of the third fraction 226 can be adjusted depending upon the desires of the operator.
The plasma fraction 224 is held in the plasma collection area 92 for later withdrawal. Therefore, the use of the plunger 60 and the buoy 14, 300 creates three distinct fractions that may be removed from the tube 12 after only one spin procedure. The fractions include the white/red blood cell fraction 222, held between the buoy 14, 300 and the tube bottom 24. The third or platelet or undifferentiated cell fraction 226 is held between the plunger 60 and the buoy 14, 300. Finally, the plasma fraction 224 is collected in the plasma collection area 92.
The third fraction 226 may be extracted from the tube 12 first, without commingling the other fractions, through the sample collection bore 68. With particular reference to
Before attempting to withdraw the third fraction 226, the separator 10 may be agitated to re-suspend the platelets and concentrated white/red blood cells in a portion of the plasma remaining in the collection face 46. This allows for easier and more complete removal of the third fraction 226 because it is suspended rather than compressed against the collection face 46. A vacuum is then created in the second syringe 210 by pulling back the plunger to draw the third fraction 226 into the second syringe 210.
As the third fraction 226 is drawn into the second syringe 210 the plunger 60 moves towards the buoy 14, 300. This action is allowed because of the vent bore 98 formed in the cap 18. Atmospheric air is transferred to the plasma collection area 92 through the vent bore 98 to allow the third fraction 226 to be removed. This allows the movement of the plunger 60 towards the buoy 14, 300. This action also allows the plunger 60 to “wipe” the collection face 46. As the plunger front face 84 mates with the collection area 46 the third fraction 226 is pushed into the sample collection aperture 86. This ensures that substantially the entire third fraction 226 collected in the collection area 46 is removed into the second syringe 210. It can also increase the repeatability of the collection volumes. In addition, because the second syringe 210 does not protrude out the sample collection aperture 86, it does not interfere with the collection of the third fraction 226. Once the plunger front face 84 has mated with the collection face 46 there is substantially no volume between the plunger 60 and the buoy 14, 300.
Once the third fraction 226 is extracted the second syringe 210 is removed from the first plunger port 22. Also the extraction of the third fraction 226 leaves the plasma fraction 224 and the red blood cell fractions 222 separated in the tube 12. At this point a third syringe 212 may be affixed to the fraction collection valve 20. The third syringe 212 is connected to the external threads 94 of the fraction collection valve 20 to ensure a liquid tight connection. It will be understood, however, that another connection mechanism such as a snap or compression engagement may be used to connect the third syringe 212 to the fraction collection valve 20.
A vacuum is then created in the third syringe 212 to draw the plasma fraction 224 from the plasma collection area 92 through the plasma collection tube 54. As discussed above, the plasma collection tube 54 is connected to the hose barb 93. Therefore, the plasma flows through the plasma collection bore 93a through the hose barb 93, and then through the plasma collection tube 54. It will be understood that the plasma collection tube 54 may alternatively simply rest on the plunger back face 88 to collect the plasma fraction 224. In this way the plasma fraction 224 may be removed from the separator 10 without commingling it with the white/red blood cell fraction 222. After the plasma fraction 224 is removed, the separator 10 may be dismantled to remove the white/red blood cell fraction 222. Alternatively, the separator 10 may be discarded in an appropriate manner while retaining the white/red blood cell fraction 222.
The separator 10 allows for the collection of three components of a bone reaming material and whole blood sample's fractions with only one centrifugation spin. The interaction of the buoy 14, 300 and the plunger 60 allows a collection of about 40% to nearly 100% of the available buffy coat in the whole blood sample portion of the mixture after a centrifuge processing time of about 5 minutes to about 15 minutes. The complimentary geometry of the plunger front face 84 and the collection face 46 help increase the collection efficiency. Although only the cone geometry is discussed herein, it will be understood that various other geometries may be used with similar results.
The plunger front face 84 being flexible also helps ensure a complete mating with the collection face 46. This, in turn, helps ensure that substantially the entire volume between the two is evacuated. The process first begins with the suction withdrawal of the third fraction 226 via the second syringe 210, but is completed with a fluid force action of the third fraction 226 as the plunger front face 84 mates with the collection face 46. As the plunger front face 84 mates with the collection face 46 the fluid force assists in removal of the selected fraction.
The plunger 60 also substantially wipes the tube wall 23. Because the plunger 60 is formed of a flexible material it forms a seal with the tube wall 23 which is movable. Therefore, substantially no liquid is able to move between the plunger wall 80 and the tube wall 23. Material is substantially only able to go past the plunger front face 84 via the check valve 90.
The complimentary geometry also helps decrease the collection time of the third fraction 226. Therefore, entire time to prepare and remove the third fraction 226 is generally about 5 to about 40 minutes. This efficiency is also assisted by the fact that the separator 10 allows for the removal of the third fraction 226 without first removing the plasma fraction 224, which includes the buffy coat, and respinning the plasma fraction 224. Rather one spin in the separator 10 with the whole blood sample allows for the separation of the buffy coat for easy extraction through the plunger 60.
The separator 10 may be used to separate any appropriate material. The material may be separated for any purpose, such as a surgical procedure. For example, a selected fraction of a whole heterogeneous material or multi-component material may be separated and purified into a desired fraction according to various embodiments. The multi-component material can be harvested from a patient by methods such as bone reaming, as depicted in
The description of the teachings is merely exemplary in nature and, thus, variations that do not depart from the gist of the teachings are intended to be within the scope of the teachings. Such variations are not to be regarded as a departure from the spirit and scope of the teachings.
This application is a divisional of U.S. patent application Ser. No. 11/441,275, filed May 25, 2006, now U.S. Pat. No. 7,832,566, issued on Nov. 16, 2010, which is a continuation-in-part of U.S. patent application Ser. No. 10/932,882, filed Sep. 2, 2004, now U.S. Pat. No. 7,374,678, issued on May 20, 2008, which is a continuation-in-part of U.S. patent application Ser. No. 10/445,381, filed May 23, 2003, now U.S. Pat. No. 7,179,391, issued on Feb. 20, 2007, which claims the benefit of U.S. Provisional Application No. 60/383,013, filed on May 24, 2002. The disclosures of the above applications are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
280820 | Hickson et al. | Jul 1883 | A |
593333 | Park | Nov 1897 | A |
1468313 | Lux | Sep 1923 | A |
1593814 | Vogel | Jul 1926 | A |
2722257 | Lockhart | Nov 1955 | A |
3013557 | Pallotta | Dec 1961 | A |
3141846 | Laven, Jr. | Jul 1964 | A |
3159159 | Cohen | Dec 1964 | A |
3300051 | Mitchell | Jan 1967 | A |
3409165 | Creith | Nov 1968 | A |
3420374 | Umeda | Jan 1969 | A |
3441143 | Kudlaty | Apr 1969 | A |
3453364 | Flodin et al. | Jul 1969 | A |
3469369 | Helmke | Sep 1969 | A |
3508653 | Coleman | Apr 1970 | A |
3545671 | Ross | Dec 1970 | A |
3583627 | Wilson | Jun 1971 | A |
3596652 | Winkelman | Aug 1971 | A |
3647070 | Adler | Mar 1972 | A |
3654925 | Holderith | Apr 1972 | A |
3706305 | Berger et al. | Dec 1972 | A |
3706306 | Berger et al. | Dec 1972 | A |
3723244 | Breillatt, Jr. | Mar 1973 | A |
3779383 | Ayres | Dec 1973 | A |
3785549 | Latham, Jr. | Jan 1974 | A |
3814248 | Lawhead | Jun 1974 | A |
3849072 | Ayres | Nov 1974 | A |
3850369 | Bull et al. | Nov 1974 | A |
3879295 | Glover et al. | Apr 1975 | A |
3894952 | Ayres | Jul 1975 | A |
3896733 | Rosenberg | Jul 1975 | A |
3897337 | Ayres | Jul 1975 | A |
3897343 | Ayres | Jul 1975 | A |
3909419 | Ayres | Sep 1975 | A |
3929646 | Adler | Dec 1975 | A |
3931010 | Ayres et al. | Jan 1976 | A |
3931018 | North, Jr. | Jan 1976 | A |
3935113 | Ayres | Jan 1976 | A |
3937211 | Merten | Feb 1976 | A |
3941699 | Ayres | Mar 1976 | A |
3945928 | Ayres | Mar 1976 | A |
3951801 | Ayres | Apr 1976 | A |
3957654 | Ayres | May 1976 | A |
3962085 | Liston et al. | Jun 1976 | A |
3965889 | Sachs | Jun 1976 | A |
3972812 | Gresl, Jr. | Aug 1976 | A |
3982691 | Schlutz | Sep 1976 | A |
4001122 | Griffin | Jan 1977 | A |
4020831 | Adler | May 1977 | A |
4046699 | Zine, Jr. | Sep 1977 | A |
4055501 | Cornell | Oct 1977 | A |
4059108 | Latham, Jr. | Nov 1977 | A |
4066549 | Oeser et al. | Jan 1978 | A |
4077396 | Wardlaw et al. | Mar 1978 | A |
4088582 | Murty et al. | May 1978 | A |
4146172 | Cullis et al. | Mar 1979 | A |
4152270 | Cornell | May 1979 | A |
4154690 | Ballies et al. | May 1979 | A |
4159896 | Levine et al. | Jul 1979 | A |
4187979 | Cullis et al. | Feb 1980 | A |
4203840 | Stoeppler et al. | May 1980 | A |
4204537 | Latham, Jr. | May 1980 | A |
4225580 | Rothman et al. | Sep 1980 | A |
4229298 | Bange | Oct 1980 | A |
4269718 | Persidsky | May 1981 | A |
4294707 | Ikeda et al. | Oct 1981 | A |
4298598 | Schwarz et al. | Nov 1981 | A |
4300717 | Latham, Jr. | Nov 1981 | A |
4303193 | Latham, Jr. | Dec 1981 | A |
4314823 | Rich, Jr. et al. | Feb 1982 | A |
4322298 | Persidsky | Mar 1982 | A |
4332351 | Kellogg et al. | Jun 1982 | A |
4362567 | Schwarz et al. | Dec 1982 | A |
4364832 | Ballies et al. | Dec 1982 | A |
4377572 | Schwarz et al. | Mar 1983 | A |
4379849 | Heimreid | Apr 1983 | A |
4411794 | Schwinn et al. | Oct 1983 | A |
4414976 | Schwarz et al. | Nov 1983 | A |
4416654 | Schoendorfer et al. | Nov 1983 | A |
4417981 | Nugent | Nov 1983 | A |
4424132 | Iriguchi et al. | Jan 1984 | A |
4427650 | Stroetmann et al. | Jan 1984 | A |
4427651 | Stroetmann et al. | Jan 1984 | A |
4442655 | Stroetmann et al. | Apr 1984 | A |
4443345 | Wells | Apr 1984 | A |
4445550 | Davis et al. | May 1984 | A |
4446021 | Aufderhaar et al. | May 1984 | A |
4453927 | Sinko | Jun 1984 | A |
4453939 | Zimmerman et al. | Jun 1984 | A |
4464167 | Schoendorfer et al. | Aug 1984 | A |
4511662 | Baran et al. | Apr 1985 | A |
4537767 | Rothman et al. | Aug 1985 | A |
RE32089 | Blatt et al. | Mar 1986 | E |
4577514 | Bradley et al. | Mar 1986 | A |
4610656 | Mortensen | Sep 1986 | A |
4617009 | Ohlin et al. | Oct 1986 | A |
4627879 | Rose et al. | Dec 1986 | A |
4631055 | Redl et al. | Dec 1986 | A |
4632761 | Bowers et al. | Dec 1986 | A |
4639316 | Eldegheidy | Jan 1987 | A |
4650678 | Fuhge et al. | Mar 1987 | A |
4655211 | Sakamoto et al. | Apr 1987 | A |
4672969 | Dew | Jun 1987 | A |
4675117 | Neumann et al. | Jun 1987 | A |
4680025 | Kruger et al. | Jul 1987 | A |
4714457 | Alterbaum | Dec 1987 | A |
4722790 | Cawley et al. | Feb 1988 | A |
4724317 | Brown et al. | Feb 1988 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4735726 | Duggins | Apr 1988 | A |
4738655 | Brimhall et al. | Apr 1988 | A |
4755300 | Fischel et al. | Jul 1988 | A |
4755301 | Bowers | Jul 1988 | A |
4770779 | Ichikawa et al. | Sep 1988 | A |
4776964 | Schoendorfer et al. | Oct 1988 | A |
4818291 | Iwatsuki et al. | Apr 1989 | A |
4818386 | Burns | Apr 1989 | A |
4828710 | Itoh et al. | May 1989 | A |
4832851 | Bowers et al. | May 1989 | A |
4834890 | Brown et al. | May 1989 | A |
4839058 | Cawley et al. | Jun 1989 | A |
4844818 | Smith | Jul 1989 | A |
4846780 | Galloway et al. | Jul 1989 | A |
4846835 | Grande | Jul 1989 | A |
4850952 | Figdor et al. | Jul 1989 | A |
4853137 | Ersson et al. | Aug 1989 | A |
4871462 | Fischel et al. | Oct 1989 | A |
4874368 | Miller et al. | Oct 1989 | A |
4877520 | Burns | Oct 1989 | A |
4879031 | Panzani et al. | Nov 1989 | A |
4900453 | Sedlmayer et al. | Feb 1990 | A |
4902281 | Avoy | Feb 1990 | A |
4909251 | Seelich et al. | Mar 1990 | A |
4915847 | Dillon et al. | Apr 1990 | A |
4917801 | Luderer et al. | Apr 1990 | A |
4928603 | Rose et al. | May 1990 | A |
4929242 | Desecki et al. | May 1990 | A |
4933291 | Daiss et al. | Jun 1990 | A |
4939081 | Figdor et al. | Jul 1990 | A |
4943273 | Pages et al. | Jul 1990 | A |
4946601 | Fiehler | Aug 1990 | A |
4950220 | Wells et al. | Aug 1990 | A |
4957637 | Cornell | Sep 1990 | A |
4957638 | Smith | Sep 1990 | A |
4973168 | Chan | Nov 1990 | A |
4983157 | Pober et al. | Jan 1991 | A |
4983158 | Headley | Jan 1991 | A |
4985153 | Kuroda et al. | Jan 1991 | A |
5000970 | Shanbhag et al. | Mar 1991 | A |
5002571 | O'Donnell, Jr. et al. | Mar 1991 | A |
5019243 | McEwen et al. | May 1991 | A |
5024613 | Vasconcellos et al. | Jun 1991 | A |
5030215 | Morse et al. | Jul 1991 | A |
5030341 | McEwen et al. | Jul 1991 | A |
5039401 | Columbus et al. | Aug 1991 | A |
5045048 | Kaleskas et al. | Sep 1991 | A |
5047004 | Wells | Sep 1991 | A |
5053127 | Schoendorfer et al. | Oct 1991 | A |
5053134 | Luderer et al. | Oct 1991 | A |
5071570 | Shiraki et al. | Dec 1991 | A |
5080262 | Herold et al. | Jan 1992 | A |
5086784 | Levine et al. | Feb 1992 | A |
5100564 | Pall et al. | Mar 1992 | A |
5104375 | Wolf et al. | Apr 1992 | A |
5112484 | Zuk, Jr. | May 1992 | A |
5112490 | Turpen | May 1992 | A |
5131907 | Williams et al. | Jul 1992 | A |
5137832 | Levine et al. | Aug 1992 | A |
5141645 | Shiraki et al. | Aug 1992 | A |
5147290 | Jonsson et al. | Sep 1992 | A |
5152905 | Pall et al. | Oct 1992 | A |
5156613 | Sawyer | Oct 1992 | A |
5165938 | Knighton | Nov 1992 | A |
5171456 | Hwang et al. | Dec 1992 | A |
5173295 | Wehling et al. | Dec 1992 | A |
5178602 | Wells | Jan 1993 | A |
5185001 | Galanakis | Feb 1993 | A |
5188583 | Guigan et al. | Feb 1993 | A |
5190057 | Sarfarazi | Mar 1993 | A |
5190759 | Lindblad et al. | Mar 1993 | A |
5197985 | Caplan et al. | Mar 1993 | A |
5203825 | Haynes et al. | Apr 1993 | A |
5204537 | Bennet et al. | Apr 1993 | A |
5206023 | Hunziker et al. | Apr 1993 | A |
5207638 | Choksi et al. | May 1993 | A |
5217426 | Bacehowski et al. | Jun 1993 | A |
5217627 | Pall et al. | Jun 1993 | A |
5219328 | Morse et al. | Jun 1993 | A |
5226877 | Epstein | Jul 1993 | A |
5226914 | Caplan et al. | Jul 1993 | A |
5234608 | Duff | Aug 1993 | A |
5236604 | Fiehler | Aug 1993 | A |
5251786 | Sarrine | Oct 1993 | A |
5258126 | Pall et al. | Nov 1993 | A |
5260420 | Burnouf-Radosevich et al. | Nov 1993 | A |
5269927 | Fiehler | Dec 1993 | A |
5271852 | Luoma, II | Dec 1993 | A |
5279825 | Wehling et al. | Jan 1994 | A |
5281342 | Biesel et al. | Jan 1994 | A |
5290552 | Sierra et al. | Mar 1994 | A |
5290918 | Bui-Khac et al. | Mar 1994 | A |
5298171 | Biesel et al. | Mar 1994 | A |
5304372 | Michalski et al. | Apr 1994 | A |
5316674 | Pall et al. | May 1994 | A |
5318524 | Morse et al. | Jun 1994 | A |
5318782 | Weis-Fogh et al. | Jun 1994 | A |
5321126 | van Dommelen et al. | Jun 1994 | A |
5322620 | Brown et al. | Jun 1994 | A |
5330974 | Pines et al. | Jul 1994 | A |
5344752 | Murphy | Sep 1994 | A |
5354483 | Furse | Oct 1994 | A |
5370221 | Magnusson et al. | Dec 1994 | A |
5370802 | Brown | Dec 1994 | A |
5372945 | Alchas et al. | Dec 1994 | A |
5376263 | Fischel | Dec 1994 | A |
5387187 | Fell et al. | Feb 1995 | A |
5393674 | Levine et al. | Feb 1995 | A |
5395923 | Bui-Khac et al. | Mar 1995 | A |
5403272 | Deniega et al. | Apr 1995 | A |
5405607 | Epstein | Apr 1995 | A |
5409833 | Hu et al. | Apr 1995 | A |
5411885 | Marx | May 1995 | A |
5417650 | Gordon | May 1995 | A |
5420250 | Lontz | May 1995 | A |
5443481 | Lee | Aug 1995 | A |
5454958 | Fiehler | Oct 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5456885 | Coleman et al. | Oct 1995 | A |
5474687 | Van Vlasselaer | Dec 1995 | A |
5480378 | Weis-Fogh et al. | Jan 1996 | A |
5484383 | Fitch, Jr. et al. | Jan 1996 | A |
5486359 | Caplan et al. | Jan 1996 | A |
5494578 | Brown et al. | Feb 1996 | A |
5494592 | Latham, Jr. et al. | Feb 1996 | A |
5501371 | Schwartz-Feldman | Mar 1996 | A |
5505685 | Antwiler | Apr 1996 | A |
5510102 | Cochrum | Apr 1996 | A |
5520885 | Coelho et al. | May 1996 | A |
5525477 | Hassouna | Jun 1996 | A |
5533518 | Vogler | Jul 1996 | A |
5560830 | Coleman et al. | Oct 1996 | A |
5575778 | Hardt et al. | Nov 1996 | A |
5577513 | Van Vlasselaer | Nov 1996 | A |
5585007 | Antanavich et al. | Dec 1996 | A |
5588958 | Cunningham et al. | Dec 1996 | A |
5589462 | Patat et al. | Dec 1996 | A |
5601711 | Sklar et al. | Feb 1997 | A |
5601727 | Bormann et al. | Feb 1997 | A |
5603845 | Holm | Feb 1997 | A |
5607579 | Latham, Jr. et al. | Mar 1997 | A |
5614106 | Payrat et al. | Mar 1997 | A |
5618663 | Delmas et al. | Apr 1997 | A |
5632895 | Tsukagoshi et al. | May 1997 | A |
5632905 | Haynes | May 1997 | A |
5641414 | Brown | Jun 1997 | A |
5641622 | Lake et al. | Jun 1997 | A |
5643192 | Hirsh et al. | Jul 1997 | A |
5643193 | Papillon et al. | Jul 1997 | A |
5645540 | Henniges et al. | Jul 1997 | A |
5646004 | Van Vlasselaer | Jul 1997 | A |
5648223 | Van Vlasselaer | Jul 1997 | A |
5649903 | Deniega et al. | Jul 1997 | A |
5663051 | Vlasselaer | Sep 1997 | A |
5674173 | Hlavinka et al. | Oct 1997 | A |
5707331 | Wells et al. | Jan 1998 | A |
5707647 | Dunn et al. | Jan 1998 | A |
5707876 | Levine | Jan 1998 | A |
5716616 | Prockop et al. | Feb 1998 | A |
5723331 | Tubo et al. | Mar 1998 | A |
5724988 | Dennehey et al. | Mar 1998 | A |
5733466 | Benebo et al. | Mar 1998 | A |
5733545 | Hood, III | Mar 1998 | A |
5736033 | Coleman et al. | Apr 1998 | A |
5738784 | Holm et al. | Apr 1998 | A |
5738796 | Bormann et al. | Apr 1998 | A |
5750025 | Holmes et al. | May 1998 | A |
5750658 | Coelho et al. | May 1998 | A |
5762798 | Wenthold et al. | Jun 1998 | A |
5785700 | Olson | Jul 1998 | A |
5786217 | Tubo et al. | Jul 1998 | A |
5788662 | Antanavich et al. | Aug 1998 | A |
5792344 | Holm | Aug 1998 | A |
5795489 | Holm et al. | Aug 1998 | A |
5795571 | Cederholm-Williams et al. | Aug 1998 | A |
5795751 | Apel | Aug 1998 | A |
5811094 | Caplan et al. | Sep 1998 | A |
5811151 | Hendriks et al. | Sep 1998 | A |
5817519 | Zelmanovic et al. | Oct 1998 | A |
5823986 | Peterson | Oct 1998 | A |
5824084 | Muschler | Oct 1998 | A |
5830359 | Knight et al. | Nov 1998 | A |
5833866 | Brown | Nov 1998 | A |
5834418 | Brazeau et al. | Nov 1998 | A |
5837150 | Langley et al. | Nov 1998 | A |
5840502 | Van Vlasselaer | Nov 1998 | A |
5853600 | McNeal et al. | Dec 1998 | A |
5860937 | Cohen | Jan 1999 | A |
5863892 | Stern et al. | Jan 1999 | A |
5865785 | Bischof | Feb 1999 | A |
5885239 | Headley et al. | Mar 1999 | A |
5889584 | Wardlaw | Mar 1999 | A |
5895346 | Wells et al. | Apr 1999 | A |
5899874 | Jonsson et al. | May 1999 | A |
5900245 | Sawhney et al. | May 1999 | A |
5906934 | Grande et al. | May 1999 | A |
5916557 | Berlowitz-Tarrant et al. | Jun 1999 | A |
5916743 | Lake et al. | Jun 1999 | A |
5918622 | Perez et al. | Jul 1999 | A |
5924972 | Turvaville et al. | Jul 1999 | A |
5934803 | Hutter | Aug 1999 | A |
5938621 | Kelly et al. | Aug 1999 | A |
5951160 | Ronk | Sep 1999 | A |
5955032 | Kelly et al. | Sep 1999 | A |
5955436 | Kunkle, Jr. | Sep 1999 | A |
5958250 | Brown et al. | Sep 1999 | A |
5958253 | Holm et al. | Sep 1999 | A |
5961210 | McCardel et al. | Oct 1999 | A |
5980734 | Itoh et al. | Nov 1999 | A |
5980757 | Brown et al. | Nov 1999 | A |
5985315 | Patat et al. | Nov 1999 | A |
5997544 | Nies et al. | Dec 1999 | A |
6007811 | Sawyer et al. | Dec 1999 | A |
6010627 | Hood, III | Jan 2000 | A |
6011490 | Tonnesen et al. | Jan 2000 | A |
6022306 | Dumont et al. | Feb 2000 | A |
6025201 | Zelmanovic et al. | Feb 2000 | A |
6027655 | Holm | Feb 2000 | A |
6049026 | Muschler | Apr 2000 | A |
6051146 | Green et al. | Apr 2000 | A |
6051147 | Bischof | Apr 2000 | A |
6053856 | Hlavinka | Apr 2000 | A |
6054122 | MacPhee et al. | Apr 2000 | A |
6063297 | Antanavich et al. | May 2000 | A |
6063624 | Kandler et al. | May 2000 | A |
6071421 | Brown | Jun 2000 | A |
6071422 | Hlavinka et al. | Jun 2000 | A |
6071423 | Brown et al. | Jun 2000 | A |
6090793 | Zimmermann et al. | Jul 2000 | A |
6096309 | Prior et al. | Aug 2000 | A |
6102843 | Kelley et al. | Aug 2000 | A |
6117425 | MacPhee et al. | Sep 2000 | A |
6123655 | Fell et al. | Sep 2000 | A |
6150163 | McPherson et al. | Nov 2000 | A |
6153113 | Goodrich et al. | Nov 2000 | A |
6183737 | Zaleske et al. | Feb 2001 | B1 |
6196987 | Holmes et al. | Mar 2001 | B1 |
6197325 | MacPhee et al. | Mar 2001 | B1 |
6200287 | Keller et al. | Mar 2001 | B1 |
6200606 | Peterson et al. | Mar 2001 | B1 |
6214338 | Antanavich et al. | Apr 2001 | B1 |
6221315 | Giesler et al. | Apr 2001 | B1 |
6245900 | Yamasaki et al. | Jun 2001 | B1 |
6264890 | Boehringer et al. | Jul 2001 | B1 |
6274090 | Coelho et al. | Aug 2001 | B1 |
6277961 | Hock et al. | Aug 2001 | B1 |
6280400 | Niermann | Aug 2001 | B1 |
6286670 | Smith | Sep 2001 | B1 |
6296602 | Headley | Oct 2001 | B1 |
6316247 | Katz et al. | Nov 2001 | B1 |
6322785 | Landesberg et al. | Nov 2001 | B1 |
6327491 | Franklin et al. | Dec 2001 | B1 |
6328765 | Hardwick et al. | Dec 2001 | B1 |
6334842 | Hlavinka et al. | Jan 2002 | B1 |
6342157 | Hood, III | Jan 2002 | B1 |
6351659 | Vilsmeier | Feb 2002 | B1 |
6355239 | Bruder et al. | Mar 2002 | B1 |
6368298 | Beretta et al. | Apr 2002 | B1 |
6368498 | Guilmette | Apr 2002 | B1 |
6398972 | Blasetti et al. | Jun 2002 | B1 |
6406671 | DiCesare et al. | Jun 2002 | B1 |
6410344 | Chung et al. | Jun 2002 | B1 |
6417004 | Brady et al. | Jul 2002 | B1 |
6440444 | Boyce et al. | Aug 2002 | B2 |
6444228 | Baugh et al. | Sep 2002 | B1 |
6464624 | Pages | Oct 2002 | B2 |
6471069 | Lin et al. | Oct 2002 | B2 |
6472162 | Coelho et al. | Oct 2002 | B1 |
6487992 | Hollis | Dec 2002 | B1 |
6508778 | Verkaart et al. | Jan 2003 | B1 |
6516953 | DiCesare et al. | Feb 2003 | B1 |
6523698 | Dennehey et al. | Feb 2003 | B1 |
6544162 | Van Wie et al. | Apr 2003 | B1 |
6544727 | Hei | Apr 2003 | B1 |
6558341 | Swisher | May 2003 | B1 |
6563953 | Lin et al. | May 2003 | B2 |
6596180 | Baugh et al. | Jul 2003 | B2 |
6623959 | Harris | Sep 2003 | B2 |
6629919 | Egozy et al. | Oct 2003 | B2 |
6638503 | Chitte et al. | Oct 2003 | B2 |
6676629 | Andrew et al. | Jan 2004 | B2 |
6719901 | Dolecek et al. | Apr 2004 | B2 |
6733471 | Ericson et al. | May 2004 | B1 |
6758978 | Bedell | Jul 2004 | B1 |
6764531 | Hogan | Jul 2004 | B2 |
6777231 | Katz et al. | Aug 2004 | B1 |
6803022 | DiCesare et al. | Oct 2004 | B2 |
6811777 | Mishra | Nov 2004 | B2 |
6830762 | Baugh et al. | Dec 2004 | B2 |
6835353 | Smith et al. | Dec 2004 | B2 |
6835377 | Goldberg et al. | Dec 2004 | B2 |
RE38730 | Wells et al. | Apr 2005 | E |
6899813 | Dolecek et al. | May 2005 | B2 |
6905612 | Dorian et al. | Jun 2005 | B2 |
6911202 | Amir et al. | Jun 2005 | B2 |
RE38757 | Wells et al. | Jul 2005 | E |
6979307 | Beretta et al. | Dec 2005 | B2 |
7011644 | Andrew et al. | Mar 2006 | B1 |
7077273 | Ellsworth et al. | Jul 2006 | B2 |
7077827 | Greenfield | Jul 2006 | B2 |
7155288 | Soykan et al. | Dec 2006 | B2 |
7179391 | Leach et al. | Feb 2007 | B2 |
7195606 | Ballin | Mar 2007 | B2 |
7223346 | Dorian et al. | May 2007 | B2 |
7273886 | Olivero et al. | Sep 2007 | B2 |
7354515 | Coull et al. | Apr 2008 | B2 |
7374678 | Leach et al. | May 2008 | B2 |
7411006 | Shanbrom | Aug 2008 | B2 |
7470371 | Dorian et al. | Dec 2008 | B2 |
7531355 | Rodriguez et al. | May 2009 | B2 |
7553413 | Dorian et al. | Jun 2009 | B2 |
7694828 | Swift et al. | Apr 2010 | B2 |
7845499 | Higgins et al. | Dec 2010 | B2 |
7901584 | Dorian et al. | Mar 2011 | B2 |
7914689 | Higgins et al. | Mar 2011 | B2 |
7987995 | Dorian et al. | Aug 2011 | B2 |
8062534 | Higgins et al. | Nov 2011 | B2 |
8567609 | Landrigan et al. | Oct 2013 | B2 |
20010009757 | Bischof et al. | Jul 2001 | A1 |
20020032112 | Pages | Mar 2002 | A1 |
20020035820 | Farris | Mar 2002 | A1 |
20020076400 | Katz et al. | Jun 2002 | A1 |
20020082220 | Hoemann et al. | Jun 2002 | A1 |
20020090711 | Karlsson | Jul 2002 | A1 |
20020104808 | Blasetti et al. | Aug 2002 | A1 |
20020114775 | Pathak | Aug 2002 | A1 |
20020161449 | Muschler | Oct 2002 | A1 |
20020169408 | Beretta et al. | Nov 2002 | A1 |
20020172666 | Sacchi et al. | Nov 2002 | A1 |
20020182664 | Dolecek et al. | Dec 2002 | A1 |
20020192632 | Hei et al. | Dec 2002 | A1 |
20030033021 | Plouhar et al. | Feb 2003 | A1 |
20030033022 | Plouhar et al. | Feb 2003 | A1 |
20030050709 | Noth et al. | Mar 2003 | A1 |
20030050710 | Petersen et al. | Mar 2003 | A1 |
20030082152 | Hedrick et al. | May 2003 | A1 |
20030185803 | Kadiyala et al. | Oct 2003 | A1 |
20030191429 | Andrew et al. | Oct 2003 | A1 |
20030205538 | Dorian et al. | Nov 2003 | A1 |
20040005246 | Efthimiadis et al. | Jan 2004 | A1 |
20040120942 | McGinnis et al. | Jun 2004 | A1 |
20040171146 | Katz et al. | Sep 2004 | A1 |
20040182395 | Brookman | Sep 2004 | A1 |
20040182788 | Dorian et al. | Sep 2004 | A1 |
20040182795 | Dorian et al. | Sep 2004 | A1 |
20040251217 | Leach et al. | Dec 2004 | A1 |
20050076396 | Katz et al. | Apr 2005 | A1 |
20050084961 | Hedrick et al. | Apr 2005 | A1 |
20050084962 | Simon | Apr 2005 | A1 |
20050109716 | Leach et al. | May 2005 | A1 |
20050130301 | McKay et al. | Jun 2005 | A1 |
20050145187 | Gray | Jul 2005 | A1 |
20050153441 | Hedrick et al. | Jul 2005 | A1 |
20050153442 | Katz et al. | Jul 2005 | A1 |
20050186120 | Dorian et al. | Aug 2005 | A1 |
20050196393 | Shanbrom | Sep 2005 | A1 |
20050196874 | Dorian et al. | Sep 2005 | A1 |
20050247715 | Ellsworth et al. | Nov 2005 | A1 |
20050260174 | Fraser et al. | Nov 2005 | A1 |
20050260175 | Hedrick et al. | Nov 2005 | A1 |
20050282275 | Katz et al. | Dec 2005 | A1 |
20060051865 | Higgins et al. | Mar 2006 | A1 |
20060057693 | Simon | Mar 2006 | A1 |
20060083720 | Fraser et al. | Apr 2006 | A1 |
20060140923 | Evangelista et al. | Jun 2006 | A1 |
20060151384 | Ellsworth et al. | Jul 2006 | A1 |
20060175242 | Dorian et al. | Aug 2006 | A1 |
20060175244 | Dorian et al. | Aug 2006 | A1 |
20060178610 | Nowakowski | Aug 2006 | A1 |
20060196885 | Leach et al. | Sep 2006 | A1 |
20060243676 | Swift et al. | Nov 2006 | A1 |
20060273049 | Leach et al. | Dec 2006 | A1 |
20060273050 | Higgins et al. | Dec 2006 | A1 |
20060278588 | Woodell-May | Dec 2006 | A1 |
20070034579 | Dorian et al. | Feb 2007 | A1 |
20070036768 | Fraser et al. | Feb 2007 | A1 |
20070075016 | Leach | Apr 2007 | A1 |
20070208321 | Leach et al. | Sep 2007 | A1 |
20080011684 | Dorian et al. | Jan 2008 | A1 |
20080164204 | Hatamian et al. | Jul 2008 | A1 |
20080173593 | Coull et al. | Jul 2008 | A1 |
20080193424 | McKale et al. | Aug 2008 | A1 |
20080210645 | Coull et al. | Sep 2008 | A1 |
20080217263 | Higgins et al. | Sep 2008 | A1 |
20080217264 | Leach et al. | Sep 2008 | A1 |
20080217265 | Leach et al. | Sep 2008 | A1 |
20080268064 | Woodell-May | Oct 2008 | A1 |
20080269762 | Simon et al. | Oct 2008 | A1 |
20080283474 | Leach et al. | Nov 2008 | A1 |
20080306431 | Yoo | Dec 2008 | A1 |
20080318317 | Roche et al. | Dec 2008 | A1 |
20090014391 | Leach et al. | Jan 2009 | A1 |
20090018313 | Shanbrom | Jan 2009 | A1 |
20090101599 | Dorian et al. | Apr 2009 | A1 |
20090192528 | Higgins et al. | Jul 2009 | A1 |
20090220482 | Higgins et al. | Sep 2009 | A1 |
20090221075 | Dorian et al. | Sep 2009 | A1 |
20090236297 | Dorian et al. | Sep 2009 | A1 |
20090250413 | Hoeppner | Oct 2009 | A1 |
20090253566 | Chavarria | Oct 2009 | A1 |
20090289014 | Hoeppner | Nov 2009 | A1 |
20100055087 | Higgins et al. | Mar 2010 | A1 |
20100186676 | Van Der Berg | Jul 2010 | A1 |
20100256595 | Leach et al. | Oct 2010 | A1 |
20100323870 | Leach et al. | Dec 2010 | A1 |
20100324450 | Leach et al. | Dec 2010 | A1 |
20110014705 | Leach et al. | Jan 2011 | A1 |
20110021334 | Leach et al. | Jan 2011 | A1 |
20110036786 | Ellsworth | Feb 2011 | A1 |
20110056893 | Leach et al. | Mar 2011 | A1 |
20110065183 | Dorian et al. | Mar 2011 | A1 |
20110077596 | Higgins et al. | Mar 2011 | A1 |
20110168193 | Leach et al. | Jul 2011 | A1 |
20110192804 | Landrigan et al. | Aug 2011 | A1 |
20110251041 | Chavarria et al. | Oct 2011 | A1 |
20120015796 | Leach et al. | Jan 2012 | A1 |
20120145652 | Leach et al. | Jun 2012 | A1 |
20120228203 | Hecker et al. | Sep 2012 | A1 |
20130068676 | Leach et al. | Mar 2013 | A1 |
20130102452 | Leach et al. | Apr 2013 | A1 |
20130196425 | Dorian et al. | Aug 2013 | A1 |
20130294983 | Dorian et al. | Nov 2013 | A1 |
Number | Date | Country |
---|---|---|
696278 | Jan 1999 | AU |
9103724 | Mar 1993 | BR |
1321138 | Aug 1993 | CA |
2182862 | Jun 1996 | CA |
2448415 | Dec 2002 | CA |
1074709 | Jul 1993 | CN |
103702729 | Apr 2014 | CN |
56103 | Oct 1860 | DE |
1443359 | Nov 1968 | DE |
4202667 | May 1993 | DE |
090997 | Oct 1983 | EP |
0102773 | Mar 1984 | EP |
0109374 | May 1984 | EP |
0142339 | May 1985 | EP |
0244834 | Nov 1987 | EP |
0253198 | Jan 1988 | EP |
0295771 | Dec 1988 | EP |
0417818 | Mar 1991 | EP |
534178 | Mar 1993 | EP |
0534178 | Mar 1993 | EP |
0592242 | Apr 1994 | EP |
1005910 | Jun 2000 | EP |
1006360 | Jun 2000 | EP |
1289618 | Mar 2003 | EP |
1406492 | Apr 2004 | EP |
1427279 | Jun 2004 | EP |
1467746 | Oct 2004 | EP |
1509326 | Mar 2005 | EP |
1670315 | Jun 2006 | EP |
1716901 | Nov 2006 | EP |
854715 | Nov 1960 | GB |
60-053845 | Mar 1985 | JP |
60250014 | Dec 1985 | JP |
2036872 | Feb 1990 | JP |
02071747 | Mar 1990 | JP |
2000199760 | Jul 2000 | JP |
02129224 | Oct 2000 | JP |
2004-305439 | Nov 2004 | JP |
200598704 | Apr 2005 | JP |
2005524451 | Aug 2005 | JP |
2006-305365 | Nov 2006 | JP |
2006527025 | Nov 2006 | JP |
2008104789 | May 2008 | JP |
WO-8400905 | Mar 1984 | WO |
WO-8802259 | Apr 1988 | WO |
WO-9010031 | Sep 1990 | WO |
WO-9222312 | Dec 1992 | WO |
WO-9305067 | Mar 1993 | WO |
WO-9308904 | May 1993 | WO |
WO-9407548 | Apr 1994 | WO |
WO-9617871 | Jun 1996 | WO |
WO-9617871 | Jun 1996 | WO |
WO-9848938 | Nov 1998 | WO |
WO-0061256 | Oct 2000 | WO |
WO-0103756 | Jan 2001 | WO |
WO-0183068 | Nov 2001 | WO |
WO-0238610 | May 2002 | WO |
WO-02060925 | Aug 2002 | WO |
WO-02098566 | Dec 2002 | WO |
WO-03015800 | Feb 2003 | WO |
WO-03024215 | Mar 2003 | WO |
WO-03053362 | Jul 2003 | WO |
WO-03088905 | Oct 2003 | WO |
WO-03092894 | Nov 2003 | WO |
WO-03099412 | Dec 2003 | WO |
WO-2004009207 | Jan 2004 | WO |
WO-2004104553 | Dec 2004 | WO |
WO-2005034843 | Apr 2005 | WO |
WO-2007127834 | Nov 2007 | WO |
WO-2007142908 | Dec 2007 | WO |
WO-2009021257 | Feb 2009 | WO |
Entry |
---|
Parchment et al., Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning, Toxicology Pathology, Society of Toxicological Pathologists, vol. 21, No. 2, 1993, pp. 241-250. |
“Cell Isolation Techniques, Methods and Materials, Working with Enzymes,” (2004) (9 pages) Worthington Biochemical Corp. |
“Cell Isolation Theory, Tissue Types,” (2004) (5 pages) Worthington Biochemical Corp. |
“Cytori Celution Cell Concentrate Device,” Exhibit 14, 510(k) Summary, FDA approval K060482 (Sep. 28, 2006). |
“Frequently Asked Questions, 1. Kits, 2. Engzymes,” (2003) 3 pages Worthington Biochemical Corp. |
“Trypsinization of Adherent Cells,” (undated) 2 pages. |
“Trypsinizing cells.” Bart's Cookbook, Web. Apr. 14, 2010. http://pingu.salk.edu/˜sefton/Hyper—protocols/trypsin.html. |
Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, M.D., et al., “An Anaphylactic Reaction to Topical Fibrin Glue”. |
Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”. |
Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, M.D., et al., “Intraoperative Procurement of Autologous Fibrin Glue”. |
Badiavas, et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells,” (Reprinted) Arch Dermatol. 139:510-516 (Apr. 2003). |
Bang, N.U., et al., “Plasma Protein Requirements for Human Platelet Aggregation” Ann. N.Y. Acad Sci, 201:280-299 (1972). |
Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports.” J Trauma 31 (3 1991): 408-11. |
Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors,” J Thorac Cardiovasc Surg 105(5 1993): 892-7. |
BioCUE™ Platelet Concentration System, Dec. 2010. (2 pages). |
Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”. |
Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Crafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866. |
Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. “Fibrin glue from single-donation autologous plasmapheresis.” Transfusion 32 (7 1992): 641-3. |
CLOTALYST™ Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostasis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages). |
Collier, B.S. et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, MD. 20014, Blood, vol. 47, No. 5 (May), 1976. |
Connolly, “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair,” Clinical Orthopaedics and Related Research 313:8-18 (1995). |
Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination,” Healing of Bone Defects, Journal of Orthopaedic Research (May 2006) pp. 877-888. |
De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow,” Cells Tissues Organs 174:101-109 (2003). |
De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow,” Immunology Letters 89:267-270 (2003). |
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass.” J Thorac Cardiovasc Surg 100 (2 1990): 281-6. |
DeUgarte, M.D., Daniel A., et al., “Future of Fat as Raw Material for Tissue Regneration,” (2007) pp. 215-219, Lippincott Williams & Wilkins, Inc. |
DiMuzio, Paul et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells,” Vasucular, vol. 14, No. 6, (2006) pp. 338-342, BC Decker, Inc. |
Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., “Fibrin Glue: A Review of its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”. |
Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. “Surgical Devices in Wound Healing Management.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., vol. Philadelphia: W.B. Saunders Company, 1992). |
Eppley, et al., “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004). |
Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. “A new autologous fibrinogen-based adhesive for otologic surgery.” Ann Otol Rhinol Laryngol 95 (1 Pt 1 1986): 40-5. |
Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003. |
First clinical results: Kuderma, H. and Helene Matras. “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven.” Wein Klin Wochenschr 87 (15 1975): 495-501. |
Floryan, K. et al. “Home Study Program: Intraoperative Use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674. |
Frasier, John K., et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1 (Mar. 2006) pp. S33-S37. |
Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches,” Pathol Biol (Paris), 53(10), Dec. 2005. |
Gibble, J. W. and P. M. Ness. “Fibrin glue: the perfect operative sealant?” Transfusion 30 (8 1990): 741-7. |
Gimble, Jeffrey M., “Adipose-Derived Stem Cells for Regenerative Medicine,” Circulation Research (2007) pp. 1249-1260, American Heart Association, Inc. |
Gomillion, Cheryl T., et al., “Stem cells and adipose tissue engineering,” Biomaterials 27, Science Direct (2006) pp. 6052-6063, Elsevier. |
GPS® III System, GPS® III Platelet Separation System, Leadership through Technology, brochure, Jul. 2007 (8 sheets). |
GPS® System, “GPS® Platelet Concentrate System,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) (9 pages). |
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” brochure, Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 6 pages. |
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
GPS®II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
GPS®II System, Gravitational Platelet Separation System, “User Manual,” Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells,” Stem Cells: Concise Review, 22, Jan. 2004. |
Guilak, Frank, et al., “Adipose-derived adult stem cells for cartilage tissue engineering,” Biorheology 41 (2004) pp. 389-399, IOS Press. |
Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angal, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69. |
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. “Autologous whole plasma fibrin gel. Intraoperative procurement.” Arch Surg 127 (3 1992): 357-9. |
Harvest SmartPrep PRP-20 Procedure Pack, “Instructions for Use”. |
Harvest Technologies brochure, SmartPrep2 (2002). |
Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source,” Cells Tissues Organs (2004) 178:2-12 Karger. |
Haynesworth, S.E. et al. “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate” 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462 (2002). |
Hennis, H. L., W. C. Stewart, and E. K. Jeter. “Infectious disease risks of fibrin glue [letter].” Ophthalmic Surq 23 (9 1992): 640. |
Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells,” Journal of Bone & Joint Surgery, 87-A(7):1430-1437 (Jul. 2005). |
International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008, which priority is also claimed of said provisional case by U.S. Appl. No. 12/395,085, filed Feb. 27, 2009. |
International Preliminary Report on Patentability completed Aug. 13, 2009 for PCT/US2008/004687 claiming benefit of U.S. Appl. No. 60/911,407, filed Apr. 12, 2007. |
International Search Report and Written Opinion mailed Jul. 2, 2008 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007. |
International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008. |
International Search Report and Written Opinion mailed Jul. 30, 2010 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009. |
International Search Report for International Application No. PCT/US/0316506 mailed Oct. 13, 2003 which claims benefit of U.S. Appl. No. 60/383,013, filed May 24, 2002. |
International Search Report for International Application No. PCT/US2007/012587 mailed Nov. 6, 2007 which claims benefit of U.S. Appl. No. 11/441,276, filed May 25, 2006. |
Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration,” 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, 1 page (2006). |
Jackson, C. M. and Y. Nemerson. “Blood coagulation.” Annu Rev Biochem 49 (811 1980): 765-811). |
Jayadev, Suprya. “Trypsinization of Adherent Cells.” Aug. 8, 1991. Web. Apr. 14, 2010 http://www.duke.edu/web/ceramide/protocols/0005.html. |
Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:S156-S162 (1999). |
Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Aug. 2000. |
Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, 1985, Helene Matras, M.D., “Fibrin Seal: The State of the Art”. |
Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2 (Feb. 1978). |
Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. “A simple method of preparation o£ autologous fibrin glue by means of ethanol.” Surg Gynecol Obstet 175 (1 1992): 72-3. |
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. “Preparation of autologous fibrin glue from pericardial blood.” Ann Thorac Sur 55 (2 1993): 543-4. |
Laryngoscope vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, M.D., et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”. |
Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, M.D., et al., “Autologous Fibrin Tissue Adhesive”. |
Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, M.D., et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”. |
Lasher, Lisa, M.D., “My Experience with PRP,” PowerPoint presentation, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report,” Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery. |
Lerner, R. and N. S. Binur. “Current status of surgical adhesives.” J Surg Res 48 (2 1990): 165-81. |
Lu, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair,” 19(1), Jan. 2002. |
Marrowstim Concentration System, Biomet Biologics, Inc., 20 pages (REV Feb. 15, 2008). |
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122 (37 1972): 517-523. |
Minntech® Filtration Technologies Group, “Hemocor HPH® Hemoconcentrator,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/hph/index.html, printed Jul. 15, 2004 (2 pages). |
Minntech® Filtration Technologies Group, “Medical Applications: Blood Filtration” Minntech Corporation (2004); http://www.minntech.com/ftg/industries/medical/blood—filter.html, printed Jul. 15, 2004 (1 page). |
Minntech® Filtration Technologies Group, “Renaflo® II Hemofilter,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/renaflo/index.html, printed Jul. 15, 2004 (2 pages). |
Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005). |
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. “A simple autologous fibrinogen glue for otologic surgery.” Otolaryngol Head Neck Surg 95 (1 1986): 122-4. |
Nakagami, Hironori, et al., “Novel Autologous Cell Tehrapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells,” Angiogenesis by Adipose Tissue-Derived Cells, 2005 pp. 2542-2547, American Heart Association, Inc. |
Nathan, Suresh,, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue,” Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc. |
Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs,” The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, Aug. 1986. |
Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, M.D., et al., “Surgical Tissue Adhesives in Otolaryngology-Head and Neck Surgery”. |
Parker, Anna M., et al., Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opinion, Cell-& Tissue-based Therapy, Expert Opin. Biol. Ther. (2006) pp. 567-578 Informa UK Ltd. |
Planat-Bénard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells,” Adipose-Derived Cell Cardiomyocyte (2004) pp. 223-229 American Heart Association, Inc. |
Ponticiello, Michael S., “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc. (2006) 2 pages. |
Rangappa, Sunil, M.D., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes,” Adult Stem Cells Transformed into Cardiomyoctyes, (2003) pp. 775-779 Ann Thorac Surg. |
Rigotti, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Pub. 2005) pp. 1409-1422. |
Rubin, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (2007) pp. 1423-1424. |
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surq 3 (3 1993): 190 (1 page). |
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. “Does fibrin glue cause foreign body reactions?” Eu r J Pediatr Surg 2 (5 1992): 285-6. |
Schmidt, K.G., et al., “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, 23:97-106 (1979). |
Schmidt, K.G., et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23:88-96 (1979). |
Schäffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies,” Tissue-Specific Stem Cells, Stem Cells® (2007) pp. 818-827 AlphaMed Press. |
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (4 1993): 309-52. |
Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet, (2003) pp. 1-2, Sigma-Aldrich, Inc. |
Swift, Mathew J., et al., “Characterization of Growth Factors in Platelet Rich Plasma,” 1-Cell Factor Technologies, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
Symphony II Platelet Concentrate System/PCS brochure; “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors,” DePuy (Jan. 2003). |
Takahashi, Kazutoshi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, (2007) pp. 1-12, Elsevier Inc. |
The American Joumal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., M.D., et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”. |
The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, M.D., et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”. |
The Sports Medicine Center, “Knee Cartilage Implantation”, Carticel™, “Autologous Cultured Chondrocyte Implantation”, http://www.orthoassociates.com/carticel.htm (printed Apr. 6, 2006). |
The Stone Clinic, “Platelet Rich Plasma (PRP)”, web site printed May 2006. |
Vox Sanquinis, vol. 68: 82-89, Feb. 1995, Boomgaard Et. al, Pooled Platelet Concentration Prepred by the . . . . |
Weis-Fogh, U. S. “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system.” Eur Surg Res 20 (5-6 1988): 381-9. |
Wiseman, David M., David T. Rovee, and Oscar M. Alverez. “Wound Dressings: Design and Use.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., Vol. Philadelphia: W. B. Saunders Company, 1992). |
Woodell-May, et al., “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting,” Scientific Foundation, Journal of Carniofacial Surgery 16(5):749-756 (Sep. 2005). |
Written Opinion of the International Preliminary Examining Authority mailed Mar. 17, 2009 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007. |
Yoon, Eulsik, M.D., Ph.D., et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model,” Tissue Engineering, vol. 13, No. 3 (2007) pp. 619-627 Mary Ann Liebert, Inc. |
Zhang, Duan-zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction,” Chinese Medical Journal, vol. 120, No. 4 (2007) pp. 300-307 General Hospital of Shenyang Military Region, Shenyang, China. |
Zuk, Patricia A., Ph.D., “Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies,” Tissue Engineering, vol. 7, No. 2, (2001) pp. 211-228 Mary Ann Liebert, Inc. |
DePalma, L., et al., “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods.” Transfusion (1993) vol. 33, No. 9; pp. 717-720. |
Friesen, M.D., Robert, et al. “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass.” Anesth. Analg 1993: 77-702-7. |
Hood, Andrew G., et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties,” (Jan. 1993) vol. 14 pp. 126-129. |
International Preliminary Report on Patentability and Written Opinion mailed Oct. 13, 2011 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009. |
Longas, Maria O., “An Improved Method for the Purification of Human Fibrinogen.” J. Biochem (1980) vol. 11, pp. 559-564. |
Marx, Gerard, et al. “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix.” Journal of Biomedical Materials Research Part B: Applied Biomaterials (Apr. 2007) pp. 49-57. |
Masri, Marwan A., et al. “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000.” Thromb Haemostas (Stuttgart) (1983) vol. 49 (2); pp. 116-119. |
Orphardt, Charles E., “Denaturation of Proteins,” Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurstedu/˜chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011). |
Silver, Frederick H., et al., “Review Preparation and use of fibrin glue in surgery.” Biomaterials 16 (1995) pp. 891-903. |
Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery,” Scand J Thor Cardiovasc Surg 22:271-274, 1988. |
Sutton, Robin G., et al. “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass.” Ann Thorac Surg (1993) vol. 56; pp. 941-943. |
Weisman, MD., Robert A., “Biochemical Characterization of Autologous Fibrinogen Adhesive,” Laryngoscope 97: Oct. 1987; pp. 1186-1190. |
“Caps for Corning® and Costar® Plastic Labware,” Technical Bulletin. (Dec. 2008) Corning, Incorporated. |
“Centrifuge Tubes” Corning Costar brochure. 1996/1997 Catalog pp. 76-77. |
“Clotalyst® Autologous Clotting Factor” brochure. (Aug. 15, 2008) Biomet Biologics. |
“Corning® 15 and 50 mL Centrifuge Tubes,” Life Sciences. (Jun. 2005) Corning Incorporated. |
“Letter CryoSeal FS System. Vaccines, Blood & Biologics,” letter. (Jul. 26, 2007) FDA U.S. Food and Drug Administation. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/Premarket ApprovalsPMAs/ucm091631.htm (Web accessed Aug. 12, 2011). |
“Plasmax® Plasma Concentration System” brochure. (Jun. 15, 2008) Biomet® Biologics. |
“Prosys PRP Kit,” brochure Tozai Holdings, Inc. http://tozaiholdings.en.ec21.com/Prosys—PRP—Kit—5467051—5467061.html Printed from Web Aug. 24, 2011. |
“Prosys PRP Kit,” Tozai Holdings, Inc. EC21 Global B2B Marketplace http://www.ec21.com/product-details/Prosys-PRP-Kit—5467061.html Printed from Web Jul. 18, 2011. |
GPS®II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Biomet Biologics (Jul. 15, 2006) 16 pages. |
International Preliminary Report on Patentability mailed Jan. 26, 2012 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009. |
International Search Report and Written Opinion mailed Aug. 9, 2011 for PCT/US2011/031954 claiming benefit of U.S. Appl. No. 12/758,127, filed Apr. 12, 2010. |
International Search Report and Written Opinion mailed Oct. 8, 2010 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009. |
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3 (1992): 190 (1 page). |
Connolly, John, M.D., et al. “Development of an Osteogenic Bone-Marrow Preparation.” The Journal of Bone and Joint Surgery, Incorporated. vol. 71-A, No. 5 (Jun. 1989) pp. 684-691. |
Hom, D., et al. “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound.” The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003. |
International Preliminary Report on Patentability and Written Opinion mailed Oct. 31, 2013 for PCT/US2012/034104 claiming benefit of U.S. Appl. No. 13/089,591, filed Apr. 19, 2011. |
English translation dated Jan. 13, 2014 for Japanese patent application No. JP2005-98704, previously cited. |
Number | Date | Country | |
---|---|---|---|
20110056893 A1 | Mar 2011 | US |
Number | Date | Country | |
---|---|---|---|
60383013 | May 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11441275 | May 2006 | US |
Child | 12946338 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10932882 | Sep 2004 | US |
Child | 11441275 | US | |
Parent | 10445381 | May 2003 | US |
Child | 10932882 | US |